The collapse of debt negotiations between Greece and the European Union weighed the markets down to a lower open with the Dow losing 35 points to 17,983. Nasdaq slipped 8 points to 4,889.
On the upside
VASCO Data Security (Nasdaq: VDSI) reported sharply higher fourth quarter earnings that more than tripled to beat analyst expectations as revenue soared.
The U. S. Patent Office granted Rosetta Genomics (Nasdaq: ROSG) a patent for cancer therapeutics. Rosetta Genomics also received its first European patent allowance for its Cancer of Unknown Primary testing franchise miR-451.
Vipshop Holdings (NYSE: VIPS) impressed with fourth quarter earnings and revenue that more than doubled.
On the downside
Celsus Therapeutics (Nasdaq: CLTX) reported disappointing results from a Phase II study of its pediatric atopic dermatitis treatment MRX-6.
Shares of National Bank of Greece (NYSE: NBG) fell after talks between Greece and the European Union collapsed.
Helix Energy (NYSE: HLX) disappointed with sharply lower fourth quarter earnings and revenue that fell short of analyst expectations.
In the broad market, declining issues outpaced advancers by a margin of more than 7 to 5 on the NYSE and by nearly 10 to 9 on Nasdaq. The broader S&P 500 eased a point to 2095. Bitcoin added $3 to $238.